Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT05104281 · UNKNOWN
Trial details
- NCT number
- NCT05104281
- Sponsor
- Qingdao Central Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-01
- Primary completion
- 2023-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.